Envoy Medical to implement 10-for-1 reverse stock split
Envoy Medical, Inc. approved and filed a Certificate of Amendment to its Articles of Incorporation to implement a 10-for-1 reverse stock split effective October 26, 2026. This acti…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Envoy Medical, Inc. approved and filed a Certificate of Amendment to its Articles of Incorporation to implement a 10-for-1 reverse stock split effective October 26, 2026. This acti…
Nova Minerals Corp has obtained final approvals for the Alaska antimony project, marking a major milestone that clears the way for construction. This development enhances the Compa…
General Motors filed an updated bylaw that mandates the board to convene a special meeting within 90 days if shareholders holding 15% of voting power submit a written request. The …
Aclaris Therapeutics announced rapid and robust responses to its bispecific antibody ATI-052 in atopic dermatitis and asthma trials, with a favorable safety profile, strong clinica…
Venu Holding Corp. has entered into an amended and restated Chapter 380 agreement with City Parties in McKinney, Texas. This document outlines the development of the Sunset Amphith…
Sculptor Diversified Real Estate Income Trust, Inc. filed an amendment to its charter to increase the authorized number of shares, with no immediate market commentary provided by t…
Longeveron's laromestrocel therapy met a secondary efficacy endpoint (MACE) in HLHS patients, triggering a meeting with the FDA despite missing the primary RVEF goal, representing …
Nathan's Famous filed a certificate detailing its corporate structure, including authorized share capital, director election rights, and limitations on director liability.
Ten patients advanced to transplant after treatment with mipletamig, a 30-fold increase over historical VEN+AZA rates, supporting further clinical development.
Pacific Rim Geological Consulting provided a QP consent for disclosure of a technical report summary for a placer gold and lode antimony deposit. The filing marks the initial resou…
International Media Acquisition Corp. is extending the deadline to complete a merger by one month to Dec. 2, 2026, the company's 24th extension letter.
Roche halted the Phase 3 IMAgINATION study due to positive results from Ionis Pharmaceuticals, where sefaxersen showed a clinically meaningful 43.1% reduction in proteinuria, a key…
The company reported robust tumor responses and durable disease control in a study of [212Pb]VMT-alpha-NET for neuroendocrine tumors, aiming to begin Phase 3 trials in 2027.
Arcosa, Inc. updated its second amended and restated certificate of incorporation to align with new Delaware law. Governance committees and the scope of waiver of the right to a st…
Aardvark reports partial data from the terminated HERO trial and intends to collaborate with the FDA on a new Phase 3 design for ARD-101. The company released more safety data as t…
ORIC Pharmaceuticals updated stakeholders on its enozertinib clinical development program on Oct 23, 2026, according to an 8-K filing.
Neuphoria Therapeutics amended its Rights Agreement, extending the Final Expiration Date from Oct 27, 2026, to Oct 27, 2027. This regulatory update does not currently impact standa…
The company amended its certificates to reduce shares of Class B convertible preferred stock from 11 million to 1.5 million, per SEC filing. The filing clarifies this affects only …
Lunai Bioworks received a determination that it no longer complies with a Nasdaq listing rule due to a shareholder deficit. The company intends to voluntarily delist its shares, su…
The Company announced early clinical improvements reported by treating physicians in a three-year-old boy at the Department of Health -- Abu Dhabi, a critical development for the p…